Gri Bio Q2 FY26 net loss narrows to $1.64 million; R&D expenses drop 78.34% to $407,000
Reuters2026/08/14 11:45- Gri Bio posted a GAAP net loss of USD 1.64 million for the quarter ended June 30, 2026, narrowing from USD 2.89 million.
- Operating loss narrowed to USD 1.65 million from USD 2.9 million as operating expenses fell to USD 1.65 million from USD 2.9 million.
- R&D spending dropped to USD 407,000 from USD 1.88 million due to completion of the Phase 2a GRI-0621 trial.
- G&A costs rose to USD 1.24 million from USD 1.02 million on higher public company expenses.
- Cash totaled USD 10.9 million at June 30, 2026; cash runway projected through Q2 2027 under the current operating plan.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises Honeywell target price to $250
Bitcoin Makes History With First-Ever Green August During a Bear Market
AI "hunger" fuels IPO boom! SB Energy (SBE.US), backed by SoftBank and OpenAI, applies for US listing.
SB Energy Corp. (SBE.US), a power infrastructure company jointly supported by SoftBank Group Corp. and OpenAI, has officially submitted an application for an initial public offering (IPO) to the U.S. Securities and Exchange Commission (SEC).
Bell Copper says Perseverance copper project drilling of hole K-24 continues in Arizona
Crypto prices
More
